Travaux subventionnés

Retour aux résultats

Synergistic combination of IAP antagonism and immunotherapy to treat brain cancers

Aperçu du projet

Brain cancers can be exceptionally challenging to treat, and new therapies are needed. Cancer cells can resist treatment in part through proteins that protect cells from dying called IAPs. Dr Robert Korneluk has found that combining IAP-blocking drugs with immunotherapy can kill cancer cells very effectively. Dr Korneluk will now define the most effective cocktail of IAP blocking drugs and immunotherapies (e.g. cancer fighting viruses and other immune system stimulants) in mice with an aggressive form of brain cancer. This will lay the foundation for clinical trials to test this new approach to brain cancer treatment.

Chef d'équipe

Robert Korneluk , University of Ottawa/CHEO

Partenaire et Donateurs

Canadian Cancer Society

Projet terminé

Synergistic combination of IAP antagonism and immunotherapy to treat brain cancers

  • Type de subvention

    Team grants

  • Domaine de recherche

    Cancer

  • Disease Area

    Brain Cancer

  • Compétition

    Subventions pour un impact de la Société canadienne du cancer

  • Province

    Ontario

  • Date de Début

    2016

  • Montant total du financement

    $1,200,000

  • Contribution Santé Canada

    $600,000